terameprocol oral (EM-1421 oral) / Erimos Pharma - LARVOL DELTA

A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR). (PubMed, Cell Rep Med) - P1 | "These findings warrant trials investigating approaches that provide sustained systemic levels of transcription inhibitors to exploit their therapeutic potential. This study was registered at ClinicalTrials.gov (NCT02575794)."

Journal • P1 data • Astrocytoma • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

Terameprocol in Treating Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1 | N=20 | Completed | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting ➔ Completed

Trial completion • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

Terameprocol in Treating Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Apr 2023 ➔ Oct 2023

Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

Tetra-O-methyl-nordihydroguaiaretic acid inhibits energy metabolism and synergistically induces anticancer effects with temozolomide on LN229 glioblastoma tumors implanted in mice while preventing obesity in normal mice that consume high-fat diets. (PubMed, PLoS One) - "Tetra-O-methyl-nordihydroguaiaretic acid (terameprocol; M4N), a global transcription inhibitor, in combination with a second anticancer drug induces strong tumoricidal activity and has the ability to suppress energy metabolism in cultured cancer cells...Meanwhile, the ability of M4N to suppress energy metabolism prevented obesity in mice consuming HF diets, indicating that M4N has beneficial effects on normal tissues. The dual ability of combination treatment with M4N to suppress both energy metabolism and oncometabolites shows that it is potentially an effective therapy for cancer."

Journal • Preclinical • Brain Cancer • CNS Tumor • Genetic Disorders • Glioblastoma • Obesity • Oncology • Solid Tumor • ATF4 • HIF1A • LDHA • NAMPT • TCF4

Terameprocol in Treating Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Apr 2023 ➔ Oct 2023 | Trial primary completion date: Dec 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor

Terameprocol in Treating Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Oct 2022 ➔ Apr 2023 | Trial primary completion date: Aug 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Brain Cancer • Glioma • Oncology • Solid Tumor

Terameprocol in Treating Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Trial primary completion date: Dec 2021 ➔ Aug 2022

Clinical • Trial primary completion date • Brain Cancer • Glioma • Oncology • Solid Tumor • MRI

Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry. (PubMed, J Pharm Biomed Anal) - "Separation of terameprocol and the internal standard, Sorafenib-methyl-d3, was achieved with a Zorbax XDB C18 column (2.1 × 50 mm, 3.5 µm) and gradient elution over a 2-minute total analytical run time...Terameprocol in plasma has been proven stable for at least 20 months when stored at -70 °C. The method was applied to the measurement of total plasma concentrations of terameprocol in a patient with a high-grade glioma receiving a 300 mg oral dose."

Journal • Brain Cancer • Glioma • Oncology • Solid Tumor

Terameprocol in Treating Patients With Recurrent High Grade Glioma (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Brain Cancer • Glioma • Oncology • Solid Tumor • MRI